GlaxoSmithKline will acquire Sirtris Pharmaceuticals Inc. for approximately $720 million in cash. The acquisition enhances GSK’s metabolic, neurology, immunology and inflammation research efforts with sirtuins, a recently discovered class of enzymes believed to be involved in the ageing process. Sirtris Pharmaceuticals has established a drug discovery capability using sirtuin modulation for the treatment of human disease. Their focus has been on the development of SIRT1 activators for the ...